Abstract Submission Guidelines

Veterinarians and researchers are invited to submit abstracts with clinical or research content related to animal leishmaniosis

The ALIVE 2 CONGRESS 2024 invites veterinarians and researchers to submit abstracts with clinical or research content related to animal leishmaniosis. Abstracts related to clinical practice or research, both prospective and retrospective, case series or clinical cases that present new or alternative information related to leishmaniosis in domestic or wild animals will be considered for evaluation. Only unpublished work will be accepted. Accepted abstracts can be presented either as an oral or poster presentation.

After evaluation of the abstract, the scientific committee will inform if your work has been accepted or rejected. In addition, they will inform you wether it needs to be an oral or poster presentation. In all cases, the ALIVE Scientific Committee’s decision will be final. Changes may be required for acceptance.

See below the topics of interest for abstract submission:

  • Epidemiology: vectorial and non-vectorial transmission, Leishmania geographic distribution, infectiousness, and reservoirs.
  • Vector biology and transmission.
  • Basic and clinical immunology.
  • Genomics, transcriptomics, proteomics and metabolomics.
  • Pathogenesis. Resistance to infection and disease.
  • Clinical and diagnostic aspects. Disease biomarkers. Coinfections.
  • Treatment, prognosis and monitoring: conventional and novel treatments, drug resistance, drug development, and immunotherapy.
  • Prevention strategies and policies.
  • One Health framework.

Key Dates

  • 1st July 2023 | Abstract Submission Opens
  • 2nd October 2023 Final Extension: 30th November 2023, 23h59 CET | Abstract Submission Deadline
  • From 18th December 2023 until 10th January 2024 | Abstract Notification

Once an abstract has been accepted, the presenting author must register for the ALIVE Congress before the 31st January 2024. Anyone whose abstract has been accepted and has not registered by the above-mentioned date will lose the option to present their work in any format whatsoever.

Submit your Abstract

Guidelines for Submission

Please read the submission guidelines carefully before submitting your abstract.
With the final extension, all abstracts must be submitted by 2nd October 2023 30th November 2023, 23h59 CET
The presenting author must be registered by 31st January 2024.

  • Only unpublished work will be accepted.
  • Abstracts must be submitted online via the website only.
  • Abstracts must be submitted and presented in clear English.
  • Presentation type: oral and poster presentations will be accepted.
  • Abstracts submitted by email will not be accepted.
  • Abstracts received after the deadline will not be considered.

Abstract Submission

You will need to fill in the abstract upload form, providing us with the following information:

  • Author’s full first and family name(s)
  • Email address
  • Affiliation details: department, institution/hospital, city, country
  • Phone number
  • Author and co-authors’ details
  • Identify any other copyright owners, including contact details
  • Presentation type: oral or poster
  • You will be able to upload your abstract in the format required

The formatting of the abstract must follow the format of BioMed Central for further publication in an open access journal. Please, read these guidelines carefully before submitting your abstract.

Abstracts must be submitted in a single, editable document (.doc, .docx). The type of presentation must be specified (oral or poster presentation).

All abstracts should be in English. You may use US English or UK English, but not a mixture.

Figures: Please make sure that figures are kept to a minimum. Figures must be included in the main text file where they are to appear and must be at least 300dpi. Figures should be numbered (e.g. Figure 1) with a short, descriptive title. This text must form part of the text file and not the figure file. Figures must be cited/called out in the text.

Tables: Please make sure that tables are kept to a minimum. Tables should be numbered (e.g. Table 1) with a short, descriptive title. Tables should be included in the document where they are to appear. Tables must be cited/called out in the text.

Formatting requirements
Abstracts with missing data cannot proceed into production. Important information to be included:

  • A citation in the text for every figure/table.
  • All referenced or even mentioned figure/table files included.
  • Affiliations in the following format: Institutions, City, [State if US], Country.
  • High resolution images (300 dpi or higher).
  • Editable tables.
  • Consistent author naming convention.
  • Accurate export from submission system, i.e. no corrupted symbols or unfinished sentences.

Consent to publish: If the abstract contains details relating to individual participants (for example a case report), written informed consent for the publication of these details must be obtained from the participants and a statement to this effect should appear at the end of the abstract.

Trial registration: If the abstract reports the results of a controlled health care intervention, the trial registry, along with the unique identifying number (e.g. Trial registration: Current Controlled Trials ISRCTN37824458) should be listed at the end of the abstract.

Title
Should be in bold, sentence case with no full stop at the end and no underlining, e.g.:
Prevalence of canine leishmaniosis in an urban area

Authors
First name, middle initials if required, and surname with no full stop at the end. Underline the name of the corresponding/presenting author. A comma should separate author names. Where authors are from a number of different institutions, the appropriate institution number from the affiliation list should be given as a superscript number immediately after each author’s name, e.g.:
John Smith1, Susan Jones1, Bill Fisher2

An asterisk * should be used to link the corresponding author with their email address, if being included.

Abstract
Limited to 800 words (including authors, affiliations, text and references). Please use single line spacing.

  • Type the text unjustified, without hyphenating words at line breaks
  • Use hard returns only to end headings and paragraphs, not to rearrange lines
  • Use the BioMed Central reference format - download here
  • Greek and other special characters may be included. If you are unable to reproduce a particular special character, please type out the name of the symbol in full
  • SI units should be used throughout (litre and molar are permitted, however)
  • Web links (URLs) should be provided in full, including both the title of the site and the URL, in the following format: Mouse Tumour Biology Database [http://tumor.informatics.jax.org/cancer_links.html]
  • Abbreviations should be kept to a minimum and should be defined when first used

Abstracts should include the following sections. Headings should be typed in bold with no colon at the end.

Background
Materials and methods
Results
Conclusions

For Case report abstracts:
Background
Case report
Conclusion

The abstract must have 800 words maximum (including authors, affiliations, text, and references) (up to five is recommended).

References
All references should be cited/called out consecutively in the text, using numbers in square brackets. Only papers that have been published, or are in press, or are available through public e-print/preprint servers should be included in the reference list.
Journal abbreviations should follow MEDLINE standards.
References should be laid out at the end of the abstract in Vancouver style and be preceded by the relevant reference number. Foreign/translated works are allowed in references, as long as they also follow Vancouver style.

1. Lastname A, Lastname B, Lastname C. Title of journal article. Journal Medline abbreviation. Year; Volume:first page-last page.
2. Lastname E. Title of book chapter. In: Lastname F, editors. Name of Book. Volume 2. 2nd edition. Place: Publisher; Year. p.first page-last page.

*Example:
Pereira, A., Cristóvão, J.M., Vilhena, H. et al. Antibody response to Phlebotomus perniciosus saliva in cats naturally exposed to phlebotomine sand flies is positively associated with Leishmania infection. Parasites Vectors. 2019; 12:1-9.

Note: Once you have submitted your work, you will not be allowed to make any changes. Revise your work carefully before submission.

Please note:

  • Do not include patient names, hospital ID numbers or other identifying information
  • Source(s) of funding must be stated
    • Authors should state ‘self-funded’ if appropriate
    • All other sources of funding should be named giving the full title of each funding body
  • Conflict(s) of interest must be stated
    • Authors should state ‘none declared’ if appropriate
    • All other potential conflicts of interest must be stated in full
    • It is the author's responsibility to consider where there may be conflicts of interest
General advice on abstract format:
  • Drug names are based on the rINN system – e.g. please use cefalexin, meticillin, ciclosporin.
  • Where products are mentioned, include the manufacturer’s name and address e.g. ciclosporin (Atopica: Novartis Animal Health, Greensboro, NC, USA).
  • Drug doses, frequencies and routes of administration should be reported (e.g mg/kg; once or twice daily).
  • Laboratory data is reported in appropriate units (e.g. IU units).
  • Breed names are adjectives, not nouns, so it is Siamese cat, not "Siamese" or Labrador retriever, not Labrador.
  • Breed names are capitalised only if they are proper names, e.g. German shepherd dog not German Shepherd Dog.
  • Numbers up to 10 should be spelled out unless associated with time (days, weeks, months, etc.).
  • It is acceptable to summarise data as follows, to conserve text: 3/9 dogs.
  • Use the following abbreviations: h for hours, min for min, sec for seconds.

Evaluation and Acceptance of the work

Once the abstracts have been received, they will be evaluated by members of the ALIVE Scientific Committee. All presenting authors will receive a notification by email of whether their abstracts were accepted or rejected from 18th December 2023 until 10th January 2024. Please ensure that the author’s email address is correct to receive the email notification promptly.

Registration for the ALIVE Congress

Once an abstract has been accepted its presenter must register for the ALIVE Congress before the 31st January 2024. Anyone whose abstract has been accepted and has not registered by the above-mentioned date will lose the option to present their work in any format whatsoever.

Guidelines for oral presentation and posters will be sent to the author’s email after acceptance of the abstract and will be available on ALIVE’s webpage.

Registration fees

The authors of the abstracts will have a special inscription rate to register for the ALIVE Congress, only and if the abstract has been accepted.

220 € | Special Early bird Registrations & payment: until 31st January 2024 for those presenting abstracts and all students and graduate students

Please, contact us if you have not received a confirmation of your abstract submission.

Guidelines for oral presentation and posters will be sent to the author’s email after acceptance of the abstract and will be available on ALIVE’s webpage.

Contact information

For any inquiries, please contact us at info@leishvet-alive.com

Submit your Abstract